clinical trial · NCT07511062
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Northside Hospital, Inc.·phase1·not yet recruiting·n = 32
Acute Myeloid LeukemiaTP53 Gene MutationDecitabineVenetoclaxAxatilimab
brief summary
Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients
started
Aug 1, 2026
primary completion
Aug 1, 2029
completion
Aug 1, 2030
last updated
Apr 6, 2026
official title
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol